Abstract
Fingolimod is a selective sphingosine-1-phosphate (S1P) receptor modulator approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) as monotherapy, in cases of first-line treatment failure, or as a first option in aggressive forms. The appearance of neoplasms is among the infrequent side effects of treatment. This is a case report on an MS patient treated with Fingolimod who developed pulmonary signet-ring cell adenocarcinoma of the lung and features a discussion of the drug’s possible involvement in the development of these types of neoplasms.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
